European Journal of Pharmacology
March 15, 2025
James J Gattuso, Carey Wilson, Shanshan Li et al.
16 citations
Psilocybin is a serotonergic psychedelic with therapeutic potential for several neuropsychiatric disorders, including depression and anxiety disorders. Serotonin transporter (5-HTT) knockout mice (KO) are a well-validated mouse model of anxiety/depression and are relevant to both chronic treatment with serotonin transporter reuptake inhibitors (SSRIs) and polymorphisms in the serotonin...
Frontiers in Psychology
September 14, 2022
Yuchao Li, Jinghui Chen, Baoxia Chen et al.
PurposeThis study systematically evaluates the effect of mindfulness meditation on depression during pregnancy. We provide evidence-based suggestions for preventing and reducing depression during pregnancy by exploring the most effective intervention mode, cycle, and frequency of mindfulness meditation.MethodsRecords were retrieved from PubMed, Web of Science, EBSCO, and Science Direct. A total...
Neuropharmacology
February 12, 2020
C. Wilson, Shanshan Li, Anthony J. Hannan et al.
Traditional monoaminergic treatments of depression frequently exhibit suboptimal tolerability and effectiveness. The 'short' (s) allele variant of 5-HTTLPR is known to compromise transcriptional efficacy of the serotonin transporter (5-HTT) and can reduce treatment response to traditional antidepressants (e.g. selective serotonin reuptake inhibitors or SSRIs). This study sought to establish the...
Cell
October 20, 2016
Tian Hua, Kiran Vemuri, Mengchen Pu et al.
Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chemical from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use. CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders. Here, we present the 2.8 Å...